Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma

Marco Maruzzo, Umberto Basso, Alberto Diminutto, Anna Roma, Fable Zustovich, Antonella Brunello, Pasquale Fiduccia, Alberto Banzato, Filiberto Zattoni, Vittorina Zagonel

Research output: Contribution to journalArticlepeer-review

Abstract

Aim, patients & methods: To evaluate the real-world setting use of sunitinib, we reviewed data of our patients from January 2007 to December 2014. Results: In 114 patients, sunitinib was used as first-line TKI. Out of 110 evaluable patients, 5 complete responses, 37 partial responses, 42 stabilizations were reported. Median progression-free survival and overall survival (OS) were 14.3 and 28.4 months. Patients who received ≥4 full-dose cycles had a better OS (p = 0.02). A neutrophil-lymphocyte ratio

Original languageEnglish
Pages (from-to)909-919
Number of pages11
JournalFuture Oncology
Volume12
Issue number7
DOIs
Publication statusPublished - Apr 1 2016

Keywords

  • dose exposure
  • neutrophil-lymphocite ratio
  • real world
  • renal cell carcinoma
  • sunitinib
  • survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this